These data were first presented by Nakul Ganju, MD, of Howard University Hospital, Washington, DC, at the 2026 Crohns and Colitis Congress on Friday, January 23, 2026, in Las Vegas, Nevada
FDA-approved GLP-1 medications (the core)
Better health begins here No insurance required No memberships or hidden fees Pay only after your appointment Important Safety Information GLP-1 agonists, including Wegovy, Zepbound, and Saxenda, may cause serious side effects including possible thyroid tumors, including cancer
Diabetes management potential Both compounds show strong potential for managing type 2 diabetes alongside obesity
For example, those with collagen vascular disorders, active infections, or poor wound healing should avoid this treatment